RC
STRO icon

RBF Capital’s Sutro Biopharma STRO Stock Holding History

RBF Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$380K Hold
15,272
– – 0.02% 399
2025
Q4 		$177K Buy
15,272
+1
+0% +$9 0.01% 526
2025
Q3 		$133K Sell
15,271
-729
-5% -$6.2K 0.01% 546
2025
Q2 		$114K Buy
+16,000
New +$131K 0.01% 566

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RBF Capital's STRO Position: Q1 2026 in Review

RBF Capital held its Sutro Biopharma (STRO) position steady in Q1 2026 at 15,272 shares worth $380K. The position accounts for 0.02% of the portfolio, ranked #399.

RBF Capital first reported a position in STRO in Q2 2025 and has held it in 4 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • RBF Capital held 15,272 shares of Sutro Biopharma worth $380K as of Q1 2026.
  • RBF Capital left its Sutro Biopharma share count unchanged in Q1 2026.
  • Sutro Biopharma made up 0.02% of RBF Capital's portfolio in Q1 2026, its #399 holding.
  • RBF Capital first reported a position in Sutro Biopharma in Q2 2025 and has held it in 4 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.